Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

FSD Pharma Triumphs in Legal Dispute Against Former CEO Dr. Raza Bokhari

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) has emerged victorious in its prolonged legal battle with the company’s former CEO, Dr. Raza Bokhari. Following years of litigation and an intensive eight-day evidentiary hearing, an arbitrator ruled against Bokhari, granting FSD Pharma three awards, including damages and compensation for the company’s arbitration-related fees and costs. On…

FTC’s Final Rule Amendment to the Health Breach Notification Rule and Its Implications

On April 26, 2024, the Federal Trade Commission (FTC) issued a significant final rule amending its Health Breach Notification Rule (HBN Rule). This amendment aims to address the evolving landscape of personal health records (PHRs) and related technologies that fall outside the regulatory scope of the Health Insurance Portability and Accountability Act of 1996 (HIPAA)….

Alaska Prepares for Potential Federal Legalization of Psychedelic Therapies

The Alaska legislature has approved a bill to create a task force dedicated to preparing the state for the potential federal legalization of psychedelic therapies. Introduced by Representative Jennie Armstrong, an Anchorage Democrat, the bill passed on May 10. The task force will not advocate for or against the use of psychedelic treatments but will…

Is Compass Pathways Poised for Success?

Compass Pathways (NASDAQ: CMPS), a leading developer in psychedelic therapy, stands at the forefront of innovative treatments for mood disorders. This makes it an exciting, albeit high-risk, investment opportunity. However, the potential for substantial returns is significant, especially with two major catalysts on the horizon that could alleviate much of the associated risk and potentially…